Myoclonic epilepsy in infancy with preceding or concurrent afebrile generalized tonic-clonic seizures in Chinese

Zhixian Yang1, Hui Li1, Jiao Xue1

  • 1Department of Pediatrics, Peking University First Hospital, Beijing, China.

Brain & Development
|July 18, 2017
PubMed

Insights

Myoclonic epilepsy in infancy (MEI) with or without afebrile generalized tonic-clonic seizures (GTCS) showed similar outcomes. Afebrile GTCS may indicate stronger cortical hyperexcitability in MEI patients.

Area of Science:

  • Neurology
  • Pediatric Epilepsy

Background:

  • Myoclonic epilepsy in infancy (MEI) is a severe form of childhood epilepsy.
  • Understanding MEI subtypes, particularly those with afebrile generalized tonic-clonic seizures (GTCS), is crucial for diagnosis and management.

Purpose of the Study:

  • To investigate the clinical characteristics and classification of MEI.
  • To compare MEI patients with and without afebrile GTCS.

Main Methods:

  • Retrospective analysis of 33 children with MEI confirmed by video-electroencephalogram (VEEG).
  • Patients were categorized based on the occurrence of afebrile GTCS relative to myoclonic seizures (MS).
  • Clinical data, VEEG features, and patient outcomes were analyzed.

Main Results:

  • No significant differences in demographics, seizure history, age at onset/control, MS duration, or psychomotor development were found among the three groups (typical MEI, MEI with preceding GTCS, MEI with concurrent GTCS).
  • Patients experiencing GTCS (groups 2 and 3) often required multiple antiepileptic drugs for seizure control compared to typical MEI.
  • Afebrile GTCS was linked to increased cortical hyperexcitability.

Conclusions:

  • MEI with or without afebrile GTCS exhibits similar clinical and EEG features and outcomes.
  • The presence of afebrile GTCS suggests heightened cortical hyperexcitability.
  • Consideration should be given to classifying MEI with preceding or concurrent afebrile GTCS as distinct subgroups or epileptic syndromes.
Abstract

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.8K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.5K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
855
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K